https://scholars.lib.ntu.edu.tw/handle/123456789/561890
標題: | The survival impact of XPA and XPC genetic polymorphisms on patients with esophageal squamous cell carcinoma | 作者: | Yang P.-W. Hsieh C.-Y. Kuo F.-T. PEI-MING HUANG HSAO-HSUN HSU SHUENN-WEN KUO JIN-SHING CHEN JANG-MING LEE |
公開日期: | 2013 | 卷: | 20 | 期: | 2 | 起(迄)頁: | 562-571 | 來源出版物: | Annals of Surgical Oncology | 摘要: | Background: The purpose of this study was to investigate the association between survival outcome of esophageal cancer patients and the genetic variants in xeroderma pigmentosum groups A (XPA) and C (XPC), 2 important molecules in the nucleotide excision pathway for DNA repair. Methods: A total of 501 patients with a diagnosis of esophageal squamous cell carcinoma (ESCC) were enrolled in the study. The genetic variants of XPA in 5′UTR and those of XPC at exon 15 K939Q were analyzed with the TaqMan assay from the genomic DNA of peripheral leukocytes and correlated to the posttreatment survival outcome. Results: Patients with XPA 5′UTR A/G and XPC K939Q C/C genotypes were found to be imposed with a higher risk of mortality after treatment compared with patients with wild-type homozygous genotypes [adjusted HR (95 % CI) of death being 1.36 (1.06-1.74) and 1.34 (0.97-1.83), respectively]. Cox's multivariate analysis detected a statistically significant increased trend in risk of mortality with the accumulation of any of these 2 unfavorable genotypes compared with patients with other genotypes [adjusted HR (95 % CI) = 1.29 (1.08-1.53), P =.005]. The effect was more pronounced in the population treated with esophagectomy (P =.023) and undergoing concurrent neoadjuvant chemoradiotherapy (CCRT) (P =.002). Conclusions: The hereditary genetic variants in XPA and XPC can serve as independent predictors of the clinical outcome of patients with ESCC, especially in those who are treated with esophagectomy and undergo chemoradiation. ? 2012 Society of Surgical Oncology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878826073&doi=10.1245%2fs10434-012-2622-x&partnerID=40&md5=3e4e495d43321b8d4581c507e5feacd4 https://scholars.lib.ntu.edu.tw/handle/123456789/561890 |
ISSN: | 1068-9265 | DOI: | 10.1245/s10434-012-2622-x | SDG/關鍵字: | cisplatin; fluorouracil; genomic DNA; paclitaxel; xeroderma pigmentosum group A protein; xeroderma pigmentosum group C protein; 5' untranslated region; adult; advanced cancer; aged; article; cancer mortality; cancer patient; cancer surgery; cancer survival; chemoradiotherapy; esophageal squamous cell carcinoma; esophagus resection; exon; female; genetic analysis; genetic polymorphism; genetic risk; genetic variability; genotype; homozygosity; human; leukocyte; major clinical study; male; outcome assessment; overall survival; predictive value; progression free survival; radiation dose; single nucleotide polymorphism; treatment response; wild type; 5' Untranslated Regions; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; DNA, Neoplasm; DNA-Binding Proteins; Esophageal Neoplasms; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Survival Rate; Tumor Markers, Biological; Xeroderma Pigmentosum Group A Protein |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。